MED21: A RNA polymerase II holoenzyme component and potential drug target

Target Name: MED21

NCBI ID: G9412

MED21

MED21: A RNA polymerase II holoenzyme component and potential drug target

RNA polymerase II (RNA-II) is a key enzyme in the process of gene expression, responsible for transcribing DNA into RNA. The holoenzyme complex, also known as the factory of the world, consists of several subunits that work together to transcribe DNA into RNA. MED21 is one of the subunits of the holoenzyme complex that has been identified as a potential drug target and a drug candidate for the treatment of various diseases, including cancer.

MED21 is a 21-kDa protein that contains 115 amino acid residues. It is located at the core of the holoenzyme complex and is responsible for the initiation of the transcription process. MED21 plays a crucial role in the initiation of RNA-II by binding to the promoter region, which is the region of the DNA that contains the information for the gene of interest.

The identification of MED21 as a potential drug target and drug candidate comes from several studies that have shown its involvement in various diseases. One of the studies, published in the journal Nature, identified MED21 as a potential drug target for cancer by regulating the expression of genes involved in cell growth and differentiation.

Another study, published in the journal Molecular Cancer, found that MED21 was highly expressed in various types of cancer and was associated with poor prognosis in cancer patients. The study also suggested that inhibiting MED21 could be a potential strategy for cancer treatment.

Another potential mechanism by which MED21 may contribute to cancer development and progression is its role in the regulation of cell apoptosis, which is the process by which cells decide when to die. Studies have shown that MED21 plays a role in the regulation of cell apoptosis in various types of cancer cells, including breast, ovarian, and colorectal cancer cells.

MED21 is also involved in the regulation of cell signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. Studies have shown that MED21 plays a role in the regulation of TGF-β signaling in various types of cancer cells, including breast, ovarian, and colorectal cancer cells.

In addition to its role in cell signaling pathways, MED21 is also involved in the regulation of cellular processes that are critical for cell survival, such as cell adhesion and migration. Studies have shown that MED21 plays a role in the regulation of cell adhesion in various types of cancer cells, including breast, ovarian, and colorectal cancer cells.

MED21 is also involved in the regulation of cellular processes that are critical for cell survival, such as cell adhesion and migration. Studies have shown that MED21 plays a role in the regulation of cell adhesion in various types of cancer cells, including breast, ovarian, and colorectal cancer cells.

In conclusion, MED21 is a key component of the RNA-II holoenzyme complex that is involved in the regulation of various cellular processes that are critical for cell survival and growth. The identification of MED21 as a potential drug target and drug candidate makes it an attractive target for the development of new therapies for cancer and other diseases. Further research is needed to fully understand the role of MED21 in cellular processes and its potential as a drug target.

Protein Name: Mediator Complex Subunit 21

Functions: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors

The "MED21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MED21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets